00007, Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, GA 30341, Telephone: (770) 488–2733, Email address: Vxm7@cdc.gov.

For program technical assistance, contact: Donald Ruberti, Senior Public Health Advisor, Prevention Services Research Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, NE, Mail Stop E46, Atlanta, Georgia 30333, Telephone: (404) 639–2098, Email address: http://www.dor1@cdc.gov. See also the CDC Home Page on the Internet: http://www.cdc.gov

To receive additional written information and to request an application kit, call 1–888-GRANTS4 (1–888–472–6874). You will be asked to leave your name and address and will be instructed to identify the Announcement number of interest.

Dated: July 27, 1999.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–19675 Filed 7–30–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99N–0926]

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Regulations Under the Federal Import Milk Act; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of July 26, 1999 (64 FR 40379). The document announced that a proposed collection of information has been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995. The document was published with an inadvertent error. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: LaJuana D. Caldwell, Office of Policy (HF–27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7010.

SUPPLEMENTARY INFORMATION: In FR Doc. 99–18927, appearing on page 40379 in the **Federal Register** of Monday, July 26, 1999, the following corrections are made:

1. On page 40379, in the first column, the Docket number is corrected to read ''99N–0926''; and in the second column, under the **SUPPLEMENTARY INFORMATION** caption, in the title of the proposed collection of information, the OMB control number ''0910–021'' is corrected to read ''0910–0212''.

Dated: July 27, 1999.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning and Legislation

[FR Doc. 99–19688 Filed 7–30–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

International Workshop on the Standardization of Whole Blood Coagulation Devices

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a workshop entitled ''International Workshop on the Standardization of Whole Blood Coagulation Devices.'' The focus of the workshop is to define the issues relating to the calibration of whole blood coagulation assays. Workshop participants will be asked to develop a proposal for standardizing the calibration of these devices. The proposal will be referred to a standards development organization.

DATE: The workshop will be held on August 13, 1999, 1 p.m. to 6 p.m.

ADDRESSES: The workshop will be held at the Washington Plaza Hotel, 10 Thomas Circle NW., Washington, DC 20005.

FOR FURTHER INFORMATION CONTACT: Sheila J. Murdock, Office of Surveillance and Biometrics (HFZ–510), Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301–594–3060, FAX 301–594–2968, e-mail ''coagulation@cdrh.fda.gov''.

SUPPLEMENTARY INFORMATION: Whole blood clotting assays are used increasingly in the point of care testing environment. The calibration of these assays against plasma methods is achieved through a variety of approaches. Consequently, the consistency of results between different devices and the traceability of results to plasma methods are variable. Limited correlation between assays can be particularly problematic when monitoring anticoagulant drugs.

The workshop will focus on defining the issues relating to the calibration of whole blood coagulation devices. Workshop participants will collaborate on a proposal for the development of a standardized approach to the calibration of these assays. The proposal will be referred to a standards development organization.

In order to make the best use of limited workshop time, guest speakers will be asked to write a draft standardization proposal prior to the date of the workshop. This document will be posted on the CDRH website after July 15, 1999, at ''http://www.fda.gov/cdrh/meetings/coag.html''. Members of the public will be encouraged to e-mail comments and recommendations about this document to ''coagulation@cdrh.fda.gov''. Summaries of all e-mailed comments sent with author's name will be posted to the website in order to provide a forum for ongoing discussion up to the week of the workshop.

Those persons interested in attending the workshop should fax or e-mail their registration including name, title, affiliation (i.e., end-user, government nonregulatory, government regulatory, industry, professional organization, proficiency testing organization, trade press, standards development organization), mailing address, telephone number, fax number, e-mail address, and area of interest. There is no charge to attend the workshop, however, advance registration is requested due to limited seating. If you need special accommodations due to a disability, please contact Shirley L. Meeks at least 7 days in advance of the meeting, at the Office of Systems Management (HFZ–17), Center for Devices and Radiological Health, Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–1283, ext. 105, FAX 301–827–2929, e-mail ''SLM@CRDH.FDA.GOV''.

Registration forms and the preliminary agenda may also be accessed at the CDRH website at ''http://www.fda.gov/cdrh/meetings/coag.html''. The workshop agenda includes presentations by guest speakers, small breakout group discussions and deliberation and refining of a standardization proposal. The final plenary session will include reports to the assembly from the smaller group discussions. Time will be provided for public comments at the end of this session. The draft standardization proposal will be finalized according to the